Cesium carbonate → 6-bromo-4-(2-methoxy-4-(trifluoromethyl)phenyl)-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide

HRID 528600ノート

反応式

HRID 528600 の反応式
[Br:1][C:2]1[C:11]([S:12]([N:15]([CH2:21][C:22]2[CH:27]=[CH:26][C:25]([O:28][CH3:29])=[CH:24][CH:23]=2)[C:16]2[S:17][CH:18]=[CH:19][N:20]=2)(=[O:14])=[O:13])=[CH:10][C:5]2[O:6][CH2:7][CH2:8][NH:9][C:4]=2[CH:3]=1.Br[C:31]1[CH:36]=[CH:35][C:34]([C:37]([F:40])([F:39])[F:38])=[CH:33][C:32]=1[O:41][CH3:42].CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.C(=O)([O-])[O-].[Cs+].[Cs+]>C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[Br:1][C:2]1[C:11]([S:12]([N:15]([CH2:21][C:22]2[CH:27]=[CH:26][C:25]([O:28][CH3:29])=[CH:24][CH:23]=2)[C:16]2[S:17][CH:18]=[CH:19][N:20]=2)(=[O:14])=[O:13])=[CH:10][C:5]2[O:6][CH2:7][CH2:8][N:9]([C:31]3[CH:36]=[CH:35][C:34]([C:37]([F:40])([F:39])[F:38])=[CH:33][C:32]=3[O:41][CH3:42])[C:4]=2[CH:3]=1

参加物

6

反応物 4

HCID 10796Cesium carbonateHCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)HCID 49911451-Bromo-2-methoxy-4-(trifluoromethyl)benzeneHCID 897618236-bromo-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide

生成物 1

HCID 897619566-bromo-4-(2-methoxy-4-(trifluoromethyl)phenyl)-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide収率 46.3%

試薬・触媒・溶媒 1

HCID 9811564Bis(dibenzylideneacetone)palladium触媒

実験手順

A vial was charged with 6-bromo-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide (107.43 mg, 0.216 mmol), 1-bromo-2-methoxy-4-(trifluoromethyl)benzene (Sigma-Aldrich, St. Louis, Mo., 193 mg, 0.757 mmol), Xantphos (25.04 mg, 0.043 mmol), Pd2(dba)3 (19.82 mg, 0.022 mmol), and cesium carbonate (212 mg, 0.649 mmol). The vessel was flushed with Ar (g), then 1,4-dioxane (2164 μl) was added. The vessel was sealed and placed in a 100° C. heating bath for 20 h. The mixture was cooled to room temperature, diluted with EtOAc, and filtered through celite. The filtrate was concentrated, and the residue was purified by chromatography on silica gel (12-g Redi-Sep Gold column, 0-50% EtOAc/Heptane) to give 6-bromo-4-(2-methoxy-4-(trifluoromethyl)phenyl)-N-(4-methoxybenzyl)-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide (67 mg, 0.100 mmol, 46.2% yield) as a yellow foam: m/z (ESI) 670.2 (M+H)+.

後処理

  1. customThe vessel was flushed with Ar (g)
  2. addition1,4-dioxane (2164 μl) was added
  3. customThe vessel was sealed
  4. customplaced in a 100° C.
  5. temperatureheating bath for 20 h
  6. additiondiluted with EtOAc
  7. filtrationfiltered through celite
  8. concentrationThe filtrate was concentrated
  9. customthe residue was purified by chromatography on silica gel (12-g Redi-Sep Gold column, 0-50% EtOAc/Heptane)

出典と根拠

ORDレコード
ord-e322cdd175624bd7bb1d25a443e0f02f
出典データセット
uspto-grants-2016_05
特許番号
US09346798B2

反応ノート

読み込み中…